Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...

Risk stratification frameworks guide NMIBC management, with intermediate-risk patients requiring nuanced decision-making due to high recurrence rates. The BCG shortage has increased reliance on ...

Intravesical therapy plays a crucial role in reducing the risk of recurrence and progression in patients with non-muscle invasive bladder cancer (NMIBC). Among the most widely used intravesical ...

Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...

Sept 10 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's (JNJ.N), opens new tab drug delivery system for a type of bladder cancer, offering a potential surgery-free ...

Sandip M. Prasad, MD, MPhil, shares his thoughts on the impact of the FDA approval of mitomycin for intravesical solution for patients with LG-IR-NMIBC. Mitomycin for intravesical solution (Zusduri; ...

New data showed a 72.2% DOR rate in patients with recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer who had a CR at 3 months. Updated data from the phase 3 ENVISION trial ...

Personalized cancer vaccines target tumor-specific neoantigens, potentially improving immune system accuracy in attacking tumors. Zusduri shows promise in treating low-grade, intermediate-risk bladder ...

After Hall of Fame athlete Deion Sanders’ announcement that he battled bladder cancer, doctors are sharing warning signs to monitor. Sanders, who is currently head football coach at the University of ...